Adam K, Allen S, Carruthers-Jones I, Oswald I, Spence M
Br J Clin Pharmacol. 1976 Feb;3(1):157-63. doi: 10.1111/j.1365-2125.1976.tb00583.x.
1 Mesoridazine, a phenothiazine of short half-life, and potentially useful as an hypnotic, has here been investigated using volunteers of late middle age. 2 The electrophsiological recording of all-night sleep was studied in seven subjects for a 7-week period during which ther received mesoridazine (10 mg nightly) for 3 weeks. The drug reduced the frequency of transitions into wakefulness and stage 1 (drowsiness) and reduced the time spent in stage 1; there was a withdrawal rebound. Mesoridazine increased REM sleep above baseline levels and a rebound fall below baseline occurred on withdrawal. The drug did not alter the amount of stage 3 + 4 slow wave sleep. 3 Subjective self-ratings were assessed in a 6-week study of sixteen subjects. Sleep quality improved on mesoridazine (10 mg nightly) but there was diminution of zest and freshness 20 min after rising. Daytime concentration and anxiety were rated as not affected either by administration or withdrawal.
美索达嗪是一种半衰期短的吩噻嗪类药物，可能具有催眠作用，本文对中年后期志愿者进行了研究。
对7名受试者进行了为期7周的研究，记录其整夜睡眠的电生理情况，在此期间，他们服用美索达嗪（每晚10毫克）3周。该药物减少了进入清醒和1期（困倦）的频率，并减少了在1期所花费的时间；停药后出现反跳。美索达嗪使快速眼动睡眠增加至基线水平以上，停药后则出现低于基线的反跳下降。该药物未改变3 + 4期慢波睡眠的量。
在一项对16名受试者进行的为期6周的研究中评估了主观自我评分。服用美索达嗪（每晚10毫克）后睡眠质量有所改善，但起床后20分钟活力和精神状态有所下降。白天的注意力和焦虑程度在服药或停药时均无变化。
